NCT04096144View on ClinicalTrials.gov

Comparison of Sugammadex and Neostigmine During PACU Stay

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 15, 2019

Primary Completion Date

March 1, 2020

Study Completion Date

June 15, 2020

Conditions
Neuromuscular Blockade
Interventions
DRUG

Neuromuscular Blocking Agents

Neuromuscular agents will be used to block muscle function for the safety and efficiency of the procedure. At the procedure's conclusion, neuromusclar agents such as Neostigmine or Sugammadex will be used to reverse the neuromuscular reversal.

Trial Locations (1)

33606

Tampa General Hospital, Tampa

All Listed Sponsors
lead

University of South Florida

OTHER